Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Author(s):
Langerak, A.W.; Ritgen, M.; Goede, V.; Robrecht, S.; Bahlo, J.; Fischer, K.; Steurer, M.; Trneny, M.; Mulligan, S.P.; Mey, U.J.M.; Trunzer, K.; Fingerle-Rowson, G.; Humphrey, K.; Stilgenbauer, S.; Bottcher, S.; Bruggemann, M.; Hallek, M.; Kneba, M.; Dongen, J.J.M. van
Published
2019
Publication type
Article / Letter to editor
Date issued
2019-01-31
Language
English
Is part of
Blood (2019), Vol. 133, no. 5, p. 494-497
hdl
1887/119612
doi
10.1182/blood-2018-03-839688